A Phase 1, Open-label, Randomized, Crossover Study to Assess the Effect of Food on the Pharmacokinetics of LY3866288 in Healthy Participants
Latest Information Update: 17 Oct 2024
At a glance
- Drugs LOXO 435 (Primary)
- Indications Solid tumours; Urogenital cancer
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 17 Oct 2024 New trial record